Cronos Group Inc. Common Share (CRON) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.06
- Estimate
- $0.05
- Surprise
- +19.1%
- Revenue (period 2026-09-30)
- $63.5M
- Score today
- 5.6/10
Revenue source: xbrl.
How the report landed
Cronos Group Inc. Common Share (CRON) reported adjusted EPS of $0.06, in line with the $0.05 estimate.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CRON Hold at 5.6/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +19.1% surprise compares with a +350.9% four-quarter average. Next scheduled report: 2027-02-25.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Positive momentum
What argues against it
- Analyst target reached - limited upside remaining
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2)
- Expensive valuation
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.61
- Stop
- $3.36
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
CRON at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.33B
- P/E (fwd)
- -90.3
- P/E (ttm)
- 22.6
- 52-week range
- $2.28–$3.91
- Off 52-week high
- 7.7%
- RSI (14)
- 67
- Volume vs avg
- 1.20×
- Score today
- 5.6/10